Increased serum levels of S100B are related to the severity of cardiac dysfunction, renal insufficiency and major cardiac events in patients with chronic heart failure

Clinical Biochemistry

Volumn 44, Issue 12, 2011, Pages 984-988

  Li, Jin Ping ^a   Lu, Lin ^a   Wang, Ling Jie ^a   Zhang, Feng Ru ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Heart failure; Renal insufficiency; S100B protein

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENHANCED GREEN FLUORESCENT PROTEIN; PROTEIN S100B; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

AGED; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HEART; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NERVE GROWTH FACTORS; PEPTIDE FRAGMENTS; REGRESSION ANALYSIS; RENAL INSUFFICIENCY; ROC CURVE; S100 PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960307305     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.05.014     Document Type: Article

References (22)

1. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668.
2. Kahn H.J., Baumal R., Van Eldik L.J., Dunn R.J., Marks A. Immunoreactivity of S100b in heart, skeletal muscle and kidney in chronic lung disease: possible induction by cAMP. Mod Pathol 1991, 4:698-701.
3. Mazzini G.S., Schaf D.V., Vinadé E.R., Horowitz E., Bruch R.S., Brunm L.M., et al. Increased S100B serum levels in dilated cardiomyopathy patients. J Card Fail 2007 Dec, 13(10):850-854.
4. Mazzini G.S., Schaf D.V., Oliveira A.R., Gonçalves C.A., Belló-Klein A., Bordignon S., et al. The ischemic rat heart releases S100B. Life Sci 2005 Jul 8, 77(8):882-889.
5. Tsoporis J.N., Marks A., Haddad A., Haddad A., Dawood F., Liu P.P., Parker T.G. S100B expression modulates left ventricular remodeling after myocardial infarction in mice. Circulation 2005, 111:598-606.
6. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003, 60:540-551.
7. Yan S.F., Berile G.R., D'Agati V., Du Yan S., Ramasamy R., Schmidt A.M. The biology of RAGE and its ligands: uncovering mechanisms at the heart of diabetes and its complications. Curr Diab Rep 2007, 2:146-153.
8. Bucciarelli L.G., Kaneko M., Ananthakrishan R., Harja E., Lee L.K., Hwang Y.C., et al. Receptor for advanced-glycation end products, a key modulator of myocardial ischemic injury. Circulation 2006, 113:1226-1234.
9. Tsoporis J.N., Izhar S., Leong-Poi H., Desjardins J.F., Huttunen H.J., Parker T.G. S100B interaction with the Receptor for Advanced Glycation End Products (RAGE): a novel receptor-mediated mechanism for myocyte apoptosis postinfarction. Circ Res 2010, 106:93-101.
10. Koyama Hidenori, Nishizawa Yoshiki AGEs ? RAGE in CKD: irreversible metabolic memory road toward CVD?. Eur J Clin Invest 2010, 40(7):623-635.
11. Hou F.F., Ren H., Owen W.F., Guo Z.J., Chen P.Y., Schmidt A.M., et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004, 15:1889-1896.
12. D'Agati V., Schmidt A.M. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol Jun 2010, 6(6):352-360. Epub 2010 Apr 27.
13. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29:2388-2442.
14. Stevens L.A., Coresh J., Greene T., Levey A. Estimating kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006, 354:2473-2483.
15. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989, 2:358-367.
16. Sorci G., Riuzzi F., Agneletti A.L., Marchetti C., Donato R. S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner. J Cell Physiol 2004, 199:274-283.
17. Brett J., Schmidt A.-M., Zou Y.-S., Yan S.-D., Weidman E., Pinsky D.J., et al. Tissue distribution of the receptor for advanced glycation endproducts (RAGE): expression in smooth muscle, cardiac myocytes, and neural tissue in addition to the vasculature. Am J Pathol 1993, 143:1699-1712.
18. Tanji N., Markowitz G.S., Fu C., Kislinger T., Taguchi A., Pischetsrieder M., et al. The expression of advanced glycation endproducts and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease. J Am Soc Nephrol 2000, 11:1656-1666.
19. Ramasamy R., Yan S.F., Schmidt A.M. RAGE: therapeutic target and biomarker of the inflammatory response-the evidence mounts. J Leukoc Biol 2009, 86:505-512.
20. Bucciarelli L.G., Ananthakrishnan R., Hwang Y.C., Kaneko M., Song F., Sell D.R., et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes Jul 2008, 57(7):1941-1951. Epub 2008 Apr 16.
21. Kenchaiah S., Evans J.C., Levy D., Wilson P.W., Benjamin E.J., Larson M.G., et al. Obesity and the risk of heart failure. N Engl J Med 2002, 347:305-313.
22. Habbu A., Lakkis N.M., Dokainish H. The obesity paradox: fact or fiction?. Am J Cardiol 2006, 98:944-948.